Compare BioNTech SE - ADR (BNTX) vs Carlyle Group Inc (CG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Carlyle Group Inc — how do they compare? BioNTech SE - ADR trades at $92.23 (market cap $23.31B), while Carlyle Group Inc trades at $48.27 (market cap $17.23B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and Carlyle Group Inc pays a 2.9% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | CG | |
|---|---|---|
Market Cap | $23.31B | $17.23B |
Sector | Health | Financials |
52-Week High | $119.34 | $69.35 |
52-Week Low | $83.89 | $40.52 |
Enterprise Value | $6.60B | — |
Dividend Yield | — | 2.9% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →
